Enlarged Spaces in Infant Brains Linked to Higher Risk of Autism, Sleep Problems

Dea Garic, PhD, and Mark Shen, PhD, both in the UNC School of Medicine’s Department of Psychiatry, have found that enlarged perivascular spaces in the brains of babies, caused by an accumulation of excess cerebrospinal fluid, have a 2.2 times greater chance of developing autism later in life.
Photo Credit: Courtesy of University of North Carolina at Chapel Hill

Throughout the day and night, cerebrospinal fluid (CSF) pulses through small fluid-filled channels surrounding blood vessels in the brain, called perivascular spaces, to flush out neuroinflammation and other neurological waste. A disruption to this vital process can lead to neurological dysfunction, cognitive decline, or developmental delays.

For the first time, researchers Dea Garic, PhD, and Mark Shen, PhD, both at the UNC School of Medicine’s Department of Psychiatry, discovered that infants with abnormally enlarged perivascular spaces have a 2.2 times greater chance of developing autism compared to infants with the same genetic risk. Their research also indicated that enlarged perivascular spaces in infancy are associated with sleep problems seven to 10 years after diagnosis.

“These results suggest that perivascular spaces could serve as an early marker for autism,” said Garic, assistant professor of psychiatry and a member of the Carolina Institute for Developmental Disabilities (CIDD).

The researchers studied infants at increased likelihood for developing autism, because they had an older sibling with autism. They followed these infants from 6-24 months of age, before the age of autism diagnosis. Their study, published in JAMA Network Open, found that thirty percent of infants who later developed autism had enlarged perivascular spaces by 12 months. By 24 months of age, nearly half of the infants diagnosed with autism had enlarged perivascular spaces.

Brain health in over 50s deteriorated more rapidly during the pandemic

Photo Credit: Gabriel Porras

Brain health in over 50s deteriorated more rapidly during the pandemic, even if they didn’t have COVID-19, according to major new research linking the pandemic to sustained cognitive decline.

Researchers looked at results from computerized brain function tests from more than 3,000 participants of the online PROTECT study, who were aged between 50 and 90 and based in the UK. The remote study, led by teams at the University of Exeter and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, and part-funded by NIHR Maudsley BRC, tested participants’ short-term memory and ability to complete complex tasks.

Through analyzing the results from this big dataset, researchers found that cognitive decline quickened significantly in the first year of the pandemic, when they found a 50 per cent change to the rate of decline across the study group. This figure was higher in those who already had mild cognitive decline before the pandemic, according to the research published in The Lancet Healthy Longevity.

High metabolism is an early sign of Alzheimer’s disease

Illustration Credit: geralt

An early phase in the process of developing Alzheimer’s disease is a metabolic increase in a part of the brain called the hippocampus, report researchers from Karolinska Institutet in a study published in Molecular Psychiatry. The discovery opens up new potential methods of early intervention.

Alzheimer’s disease is the most common form of dementia and strikes about 20,000 people in Sweden every year. Researchers now show that a metabolic increase in the mitochondria, the cellular power plants, is an early indicator of the disease. 

The teams behind the study used mice that developed Alzheimer’s disease pathology in a similar way to humans. The increase in metabolism in young mice was followed by synaptic changes caused by disruption to the cellular recycling system (a process known as autophagy), a finding that was awarded the Nobel Prize in Physiology or Medicine in 2016. 

After a time, metabolism in the Alzheimer brain usually declines, which contributes to the degradation of synapses. This the researchers could also see in the older mice, which had had the disease for a longer time. 

New genes linked to ADHD identified potentially paving the way for new treatments

Image Credit: Braňo

Several new genes associated with conditions such as Attention-deficit hyperactivity disorder (ADHD) have been identified, unearthing a significant connection between these disorders and our immune system that could lead to new treatments. The research from the University of Surrey also confirms the role of gene ADGRL3 in conditions such as ADHD, giving scientists a greater understanding of its workings.

During this innovative study, scientists led by Dr Matt Parker from Surrey set out to understand more about ADGRL3, a gene closely linked to ADHD and other ‘externalizing’ disorders, in promoting behaviors such as substance abuse, which can be associated with the conditions. Through this work, scientists identified several new genes related to externalizing disorders, which could lead to the development of new medication to lessen the impact on individuals.

An unexpected link between 2 schizophrenia risk proteins

The study findings suggest that when the proteins don’t bind properly, signaling among neurons, illustrated above, becomes imbalanced, which can lead to related negative behavioral symptoms.
 Image Credit: T. Ahmed, A. Buonanno, National institute of Child Health and Human Development

The discovery of a physical interaction between two proteins in brain cells that can be traced in mice to control of movement, anxiety and memory could one day open the door to development of new schizophrenia treatment strategies.

The research group is the first to determine that the two proteins, both among the dozens of proteins related to risk for the development of schizophrenia, bind to each other under normal conditions in multiple regions of the brain, and that their connection was found in mice to be key to maintaining normal movement, memory function and anxiety regulation.

When that connection doesn’t happen as it should, they found, behavior can be negatively affected – in mice, disruption to the proteins’ ability to interact increased hyperactivity, reduced risk avoidance and impaired memory. Though delusions and hallucinations are hallmark symptoms of schizophrenia, the condition also encompasses additional symptoms, including movement and memory problems. 

“These two proteins are seemingly unrelated, and our study has provided a link between them that wasn’t recognized before,” said lead author Chen Gu, associate professor of biological chemistry and pharmacology in The Ohio State University College of Medicine.  

Brain implant at OHSU successfully controls both seizures and OCD

OHSU neurosurgeon Ahmed Raslan, M.D., and patient Amber Pearson.
Photo Credit: OHSU/Christine Torres Hicks

A patient at Oregon Health & Science University is the first in the world to benefit from a single stimulator implanted in the brain to effectively control two life-altering conditions: seizures caused by epilepsy and compulsive behavior caused by obsessive-compulsive disorder, or OCD.

Amber Pearson, 34, of Albany, said her seizures are under better control, but the relief from her psychiatric condition is profound.

“OCD is worse than having the seizures,” she said. “Epilepsy brings limitations to my life, but OCD controlled it.”

In the case study, published in the journal Neuron, co-authors from institutions across the country describe the interactive programming of the responsive neurostimulation system, or RNS, that now functions seamlessly to control the compulsions that once ruled her life.

“Before I started treatment with my RNS, I would wash my hands until they would bleed,” Pearson said. “My hands would be so dry that bending my fingers would crack the skin of my knuckles.”

Simple blood test can help diagnose bipolar disorder

Providing a drop of blood for a test 
Photo Credit: Cambridge Centre for Neuropsychiatric Research

The researchers, from the University of Cambridge, used a combination of an online psychiatric assessment and a blood test to diagnose patients with bipolar disorder, many of whom had been misdiagnosed with major depressive disorder.

The researchers say the blood test on its own could diagnose up to 30% of patients with bipolar disorder, but that it is even more effective when combined with a digital mental health assessment.

Incorporating biomarker testing could help physicians differentiate between major depressive disorder and bipolar disorder, which have overlapping symptoms but require different pharmacological treatments.

Although the blood test is still a proof of concept, the researchers say it could be an effective complement to existing psychiatric diagnosis and could help researchers understand the biological origins of mental health conditions. The results are reported in the journal JAMA Psychiatry.

Bipolar disorder affects approximately one percent of the population – as many as 80 million people worldwide – but for nearly 40% of patients, it is misdiagnosed as a major depressive disorder.

People with severe mental illness at 50 per cent higher risk of death following COVID-19 infection

Photo Credit: Darina Belonogova

New research from King’s College London has found that people in the UK with severe mental illness were at increased risk of death from all causes following COVID-19 infection compared to those without severe mental illness.

Published in the British Journal of Psychiatry, the study investigated the extent to which having severe mental illness, which includes schizophrenia and psychosis, increased the risk of death during the first two waves of the COVID-19 pandemic.

Researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and ESRC Centre for Society and Mental Health analyzed data from over 660,000 UK patients between February 2020 and April 2021.

Among the 7146 people with severe mental illness, there was a 50 per cent greater risk of death from all causes following COVID-19 infection compared with those without severe mental illness.

Black Caribbean/Black African people were at 22 per cent higher risk of death following COVID-19 infection than White people, and this was similar for people with and without severe mental illness. However, in around 30 per cent of patient data, ethnicity was not recorded.

Case report shows promising results using transcranial magnetic stimulation for post-stroke ataxia

Image Credit: UCLA| Health et al. Cerebellum. October 21, 2023

In a new case report, researchers at UCLA Health describe promising results using repetitive transcranial magnetic stimulation (rTMS) in the management of post-stroke cerebellar ataxia, a debilitating condition marked by impaired coordination and balance.

Cerebellar ataxia describes a group of neurological disorders that affect coordination, balance, and control of muscle movements. It results from damage or dysfunction of the cerebellum, a part of the brain responsible for coordinating voluntary movements. Ataxia can manifest as unsteady walking, difficulties with fine motor skills, and problems with speech, among other symptoms. The severity of ataxia can vary from mild to severe, and treatments often aim to manage symptoms and improve a person's quality of life as treatment options are limited.

Writing in The Cerebellum, researchers led by Evan Hy Einstein, Department of Psychiatry & Biobehavioral Sciences at the UCLA David Geffen School of Medicine, report on the case of a 58-year-old male who had experienced a cerebellar hemorrhage approximately 12 years previously. Despite intensive rehabilitation, symptoms such as slow and unsteady gait, balance issues, and urinary incontinence persisted over the years. The patient sought consultation for potential rTMS treatment. His primary complaints focused on his slow and unsteady gait, along with challenges related to balance and stability. The decision was made to employ bilateral cerebellar rTMS, representing an innovative approach to address the condition.

New Research Suggests Why Males and Females Respond Differently to Social Stress

Emily Wright, researcher, in a UC Davis lab.
Photo Credit: Jerry Tsai

Women are nearly twice as likely as men to be diagnosed with an anxiety disorder, but among boys and girls the likelihood is the same. New University of California, Davis, research has identified changes in the brain during puberty that may account for differences in how women and men respond to stress.

A team of psychologists has found that testosterone is the key hormone that drives gender-based differences in responses to social stress. The study encompassed six separate experiments with mice to isolate what changes in the brain drive these differences between males and females. The study was published in the Proceedings of the National Academy of Sciences, or PNAS, today.

“This research shows how the body’s hormones shape the complex interplay between the brain’s circuitry and behavioral responses to stress,” said Brian Trainor, a professor of psychology in the College of Letters and Science at UC Davis and the study’s corresponding author.

The emotional function of dreams is not the same everywhere

The study by the UNIGE and the University of Toronto shows that there is a strong link between our socio-cultural life and the function of dreams.
Photo Credit: Maeghan Smulders

Why do we dream? A product of our brain’s neurophysiology, dreaming is a complex experience that can take on many emotional tones and simulate reality to varying degrees. As a result, there is still no clear answer to this question. A study led by the universities of Geneva (UNIGE) and Toronto, and the Geneva University Hospitals (HUG), compared the dreams of two forager communities, in Tanzania and the Democratic Republic of Congo, with those of individuals living in Europe and North America. It showed that the first two groups produced more threatening, but also more cathartic and socially-oriented dreams than the Western groups. These results, to be read in Scientific Reports, show how strong the links are between the socio-cultural environment and the function of dreams.

Dreaming is a hallucinatory experience common to all human beings. It occurs most often during the paradoxical phase of sleep, known as the Rapid Eye Movement (REM) phase. However, it can occur at any sleep stage. What are the physiological, emotional or cultural functions of dreams? Does it regulate our emotions? Does it prepare us to deal with a specific situation? Recent theories suggest that during a "functional" dream, the individual simulates more threatening and/or social situations, which would have an evolutionary advantage in promoting adapted behavior to real-life situations.

Cannabis intoxication triggers cognitive mechanism of addiction

Photo Credit: Matthew Brodeur

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and the University of Oxford has found that the main component of cannabis, delta-9-tetrahydrocannabinol (THC), leads to people’s attention being more drawn to other cannabis stimuli when using the drug, which researchers suggest could underpin the cognitive mechanisms behind cannabis use disorder (CUD).

The research, published in Addiction, also found that levels of cannabidiol (CBD) typically found in cannabis had no modulating effects on the participants, despite many users believing this to be the case.

Over the course of four sessions, researchers asked 46 infrequent cannabis users (using cannabis less than once a week) to inhale a cannabis vapour containing 10mg of THC, and either 0, 10, 20, or 30mg of CBD. They were then given a task designed to measure what they focused on more when given the choice between options of images (cannabis stimuli vs neutral and food stimuli vs neutral).

Researchers found that the acute inhalation of THC resulted in people being more drawn to cannabis-related cues without explicitly liking it more.

Cellular Atlas of Amygdala Reveals New Treatment Target for Cocaine Addiction

The study was led by co-senior authors Francesca Telese, PhD (left) and Graham McVicker, PhD (right).
Photo credit: UC San Diego Health Sciences

Researchers at University of California San Diego School of Medicine and the Salk Institute for Biological Studies have created a unique, cell-by-cell atlas of the amygdala, a small structure deep within the brain that plays a crucial role in controlling emotional responses to drugs. The findings, published October 5, 2023 in Nature Neuroscience, helped the researchers identify a potential new treatment for cocaine addiction, a disease that is poorly understood at the molecular level and has virtually no approved pharmacological treatments.

“There are some drugs that can help treat other addictions, such as those to opioids or nicotine, but there are currently no safe and effective drugs approved for cocaine addictions,” said co-senior author Francesca Telese, PhD, an associate professor in the Department of Psychiatry at UC San Diego School of Medicine. “These findings help address that problem and could also point to universal molecular mechanisms of addiction that we haven’t understood until now.”

Cocaine is a widely used illicit drug and addiction to cocaine is a major public health concern, associated with a rising number of overdose deaths and a high rate of relapse. Despite the threat cocaine addiction poses, not every person who uses cocaine develops an addiction. According to the National Institute on Drug Abuse, an estimated 4.8 million people used cocaine in 2021, while only 1.4 million people had a cocaine use disorder.

Psychedelics improve mental health, cognition in special ops veterans

The Colorado River toad (Incilius alvarius), also known as the Sonoran Desert toad, is a toad species found in northwestern Mexico and the southwestern United States. It is well known for its ability to exude toxins from glands within its skin that have psychoactive properties.
Photo Credit: Alan Schmierer
(CC0 1.0 DEED)

One treatment each of two psychedelic drugs lowered depression and anxiety and improved cognitive functioning in a sample of U.S. special operations forces veterans who sought care at a clinic in Mexico, according to a new analysis of the participants’ charts. 

The treatment included a combination of ibogaine hydrochloride, derived from the West African shrub iboga, and 5-MeO-DMT, a psychedelic substance secreted by the Colorado River toad. Both are designated as Schedule I drugs under the U.S. Controlled Substances Act.

In addition to relieving symptoms of post-traumatic stress disorder (PTSD), the combined treatment also alleviated cognitive impairment linked to traumatic brain injury – which stood out to researchers from The Ohio State University who led the chart-review analysis. Many special operations forces veterans seeking treatment for complex psychiatric symptoms do not respond to more traditional therapies. 

“What sets this group apart from some other veterans and civilians is that often, they are exposed to repeated traumatic events as a routine part of their jobs. This build-up of exposure to these difficulties seems to produce a cluster of challenges that include traumatic brain injury, which we know in and of itself predisposes people to mental health problems,” said lead author Alan Davis, associate professor and director of the Center for Psychedelic Drug Research and Education (CPDRE) in Ohio State’s College of Social Work. 

“So, the fact that we saw that there were improvements in cognitive functioning linked to brain injury were probably the most striking results, because that’s something we didn’t predict and it’s very new and novel in terms of how psychedelics might help in so many different domains.” 

Small doses of mushrooms can have a beneficial effect on mental disorders

"Liberty Cap" Psilocybin mushroom
Photo Credit: Ameruverse Digital Marketing Media

A new research result from the University of Southern Denmark opens the door to the possibility of using psilocybin, the active compound in mushrooms with psychedelic properties, as a therapeutic tool through microdosing.

Psilocybin has long been recognized as a classic psychedelic substance and has recently been investigated for its potential to assist in the treatment of various psychiatric disorders, primarily depression and addiction, through therapy supplemented with a high dose of psilocybin.

In such therapeutic treatment, the patient takes psilocybin after thorough therapeutic preparation and undergoes a psychedelic experience in a supportive environment with a trained therapist. Subsequently, the experience is integrated over several therapy sessions.

Experiments are being conducted with patients at hospitals, including Bispebjerg Hospital and Rigshospitalet.

Discrimination alters brain-gut ‘crosstalk,’ prompting poor food choices and increased health risks

Illustration Credit: julientromeur

People frequently exposed to racial or ethnic discrimination may be more susceptible to obesity and related health risks in part because of a stress response that changes biological processes and how we process food cues. These are findings from UCLA researchers conducting what is believed to be the first study directly examining effects of discrimination on responses to different types of food as influenced by the brain-gut-microbiome (BGM) system.

The changes appear to increase activation in regions of the brain associated with reward and self-indulgence – like seeking “feel-good” sensations from “comfort foods” – while decreasing activity in areas involved in decision making and self-control.

“We examined complex relationships between self-reported discrimination exposure and poor food choices, and we can see these processes lead to increased cravings for unhealthy foods, especially sweet foods, but also manifested as alterations in the bidirectional communication between the brain and the gut microbiome,” said Arpana Gupta, PhD, a researcher and co-director of the UCLA Goodman-Luskin Microbiome Center and the UCLA G. Oppenheimer Center for Neurobiology of Stress and Resilience.

Sleep apnea link to cognitive decline

Photo Credit: SHVETS production

Flinders University experts are working on better solutions for sleep apnea to ward off a range of health risks, including cognitive decline.

Improved solutions for obstructive sleep apnea (OSA), insomnia and other sleep disorders are being developed by the Flinders Sleep Health experts to reduce the associated negative health effects such as cardiovascular harm, diabetes, anxiety and depression and even long-term cognitive decline.

Heightened risk of cognitive function decline from undiagnosed OSA – particularly in middle-aged men living in the community – is the focus of one of the latest studies published in Sleep Health.

The study recorded the sleep patterns of more than 470 men aged from 41-87 years alongside their daytime cognitive function for processing speed, visual attention, episodic memory recollection and other markers.

Measuring distinct features of brain electrical activity during non-REM sleep, called ‘sleep spindles’, the study aimed to explore if these features can serve as markers of cognitive function.

“Non-REM sleep includes light stage 1 and 2 sleep, as well as deeper stage 3 sleep which is thought to play an important role in learning and memory,” says Flinders University sleep researcher Dr Jesse Parker.

New study links contraceptive pills and depression

According to the study, women who began to use contraceptive pills as teenagers had a 130 per cent higher incidence of symptoms of depression.
Photo Credit: Thought Catalog

Women who used combined contraceptive pills were at greater risk of developing depression than women who did not, according to a new study from Uppsala University. Contraceptive pills increased women’s risk by 73 per cent during the first two years of use.

In a global perspective, depression is the leading cause of ill health and disability. More than 264 million people are affected and at least 25 per cent of all women and 15 per cent of all men experience a depression that requires treatment at some point during their life.

The possibility that contraceptive pills might have negative effects on mental health and even lead to depression has long been discussed. Although many women choose to stop using contraceptive pills because of the influence on their mood, until now the picture emerging from research has not been straightforward. This study is one of the largest and widest-ranging to date, following more than a quarter of a million women from UK Biobank from birth to menopause.

Newly discovered brain mechanism linked to anxiety, OCD

Distinguished Professor Mario Capecchi, Ph.D. and Naveen Nagajaran, Ph.D.
Photo Credit: Charlie Ehlert/U of U Health

The pandemic and its aftermath have raised anxiety to new levels. But the roots of anxiety-related conditions, including obsessive-compulsive spectrum disorder (OCSD), are still unclear. In a new study, University of Utah Health scientists discovered insights into the importance of a minor cell type in the brain—microglia—in controlling anxiety-related behaviors in laboratory mice. Traditionally, neurons—the predominant brain cell type—are thought to control behavior.

The researchers showed that, like buttons on a game controller, specific microglia populations activate anxiety and OCSD behaviors while others dampen them. Further, microglia communicate with neurons to invoke the behaviors. The findings, published in Molecular Psychiatry, could eventually lead to new approaches for targeted therapies.

“A small amount of anxiety is good,” said Nobel Laureate Mario Capecchi, Ph.D., a distinguished professor of human genetics at the Spencer Fox Eccles School of Medicine at University of Utah and senior author of the study. “Anxiety motivates us, spurs us on, and gives us that extra bit of push that said, ‘I can.’ But a large dose of anxiety overwhelms us. We become mentally paralyzed, the heart beats faster, we sweat, and confusion settles in our minds.”

Clinically relevant deficiency of the “bonding hormone” oxytocin demonstrated

The hormones oxytocin and vasopressin are produced in the same area of the brain and are also very similar in structure. This is why disorders that cause vasopressin deficiency could also affect the neurons that produce oxytocin
Image Credit: Colin Behrens

The hormone oxytocin is important for social interaction and to control emotions. A deficiency of this hormone has previously been assumed, for example, in people with autism, but has never been proven. Now, for the first time, researchers from the University of Basel and the University Hospital of Basel have succeeded in demonstrating a deficiency of oxytocin in patients with a deficiency of vasopressin caused by a disease of the pituitary gland. This finding could be key to developing new therapeutic approaches.

The hormones oxytocin and vasopressin are produced in the same area of the brain and are also very similar in structure. Patients with a rare deficiency of vasopressin cannot concentrate their urine and lose liters of water as a result. In order to compensate for this loss, they are obliged to drink up to 10 liters or more per day.

With a nasal spray or a tablet containing synthetically produced vasopressin, these symptoms can usually be treated without any problems. However, even with this treatment, many patients report anxiety, have trouble with social interactions or demonstrate impaired emotional awareness.